Overall verdict
Buy
7.0/10
1-year performance
+31.12%
Score breakdown
Up 31.1% over 1 year, 94% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Growth 4.5/10.
28 analysts, target +0.1% vs the price.
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Tumor Associated Antigens (TAA) mAb Technology, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh.
It engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services ; research and development in relation to biologics ; international sales contracting service ;
vaccine contract development and manufacturing organization (CDMO) and related business ; development, production, and distribution of biotechnological products ; and engages in investment and material supplier activities. WuXi Biologics (Cayman) Inc. was incorporated in 2014 and is headquartered in Wuxi, China.
Sector
Health Care
Industry
Life Sciences Tools and Services
Primary listing
Hkex
China
CEO
Zhisheng Chen
Founded
2014
Employees
13 252
Revenue / employee
1.6M CNY
Next earnings
November 25, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
54.45 HKD
52-week low
28.48 HKD
1-year performance
31.12%
Rising
Year-to-date performance
70.42%
Rising
Drawdown
-2.66%
Near its high
Position in the 52-week range
94% of range
Range: 42.12 HKD - 78.78 HKD (comparables only)
The price implies growth of 14.15% per year; the company grows at 22.79%.
Gross margin 47.4%, net margin 21.2%, ROIC 10.2%, ROE 10.7%.
Net margin
21.19%
Exceptional
Sector 5.47%|S&P 12.97%
Gross margin
47.44%
Fair
Return on equity (ROE)
10.68%
Exceptional
Sector 3.01%|S&P 16.52%
Return on invested capital (ROIC)
10.21%
Exceptional
Free cash flow margin (FCF)
18.82%
Exceptional
Profit-to-cash conversion (FCF conversion)
0.89x
High
Margin stability
5.6 pts
Uneven
Revenue to net income
Growth
4.5/10Revenue up 18.4% over 1 year, 30.2% a year over 5, EPS 22.8% a year over 5.
Revenue (trailing 12 months)
24.2Md CNY
Revenue growth (1y)
18.40%
Hyper-growth
Revenue growth (3y)
33.09%
Solid
EPS growth (1y)
4.30%
Moderate
EPS CAGR (5y)
22.79%
Exceptional
EPS revisions (3 months)
7.84%
Sharply revised up
Valuation
6.9/10P/E 37.2x, forward P/E 32.1x, EV/EBITDA 18.5x, PEG 1.63.
P/E (TTM)
37.2x
Fair
Sector 50.3x|S&P 23.3x
Forward P/E
32.1x
Fair
EV / EBITDA
18.5x
Fair
Sector 28.4x|S&P 14.6x
PEG
1.63
Expensive
Sector 0.12|S&P 0.86
Fair value (reverse DCF)
60.45 HKD
Undervalued
Market cap
183Md CNY
Financial strength
10.0/10Cash covers 478.4% of the debt, net debt/EBITDA -1.5x.
Net debt / EBITDA
-1.5x
Net cash
Gearing (net debt / equity)
-18.92%
Net cash
Cash
13.8Md CNY
Cash / market cap
7.54%
Tight
Cash / total debt
478.37%
Net cash
Net debt
-10.9Md CNY
Equity
57.7Md CNY
Closed daily candles, 2 years
Last close on September 25, 2026: 53.00 HKD
- MM2050.03
- MM5046.40
- MM20037.89
- RSI 1464.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+5.05%
200-day average slope, 3 months
+7.45%
50-day average slope, 1 month
+15.44%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.29 % per day
Volatility change
-20.98%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 1.41 (19) | 1.55 (14) | 25 704 (23) | 9 901 (21) | 5 676 (19) |
| 2027 | 1.72 (20) | 1.85 (15) | 30 734 (25) | 12 082 (21) | 7 141 (21) |
Amounts in millions of CNY, EPS in CNY per share. In brackets, the number of analysts. Consensus as of September 22, 2026.
Same sub-industry: 103 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603259 | 7.9 | 8.0 | 72.9Md USD | 22.2x | 40.2 % | 47.7 % | 29.5 % | -1.7x | 2.7 % | 56.1 % | ||
| 2 | A207940 | 7.5 | 7.9 | 46.0Md USD | 31.8x | 39.9 % | 30.2 % | 16.6 % | -0.2x | 2.3 % | -13.0 % | ||
| 3 | IQV | 7.0 | 7.0 | 44.1Md USD | 33.2x | 8.1 % | 8.8 % | 6.8 % | 4.1x | 5.0 % | 50.6 % | ||
| 4 | 2269 | 7.0 | 7.3 | 27.2Md USD | 37.2x | 21.2 % | 18.4 % | 10.2 % | -1.5x | 2.5 % | 31.1 % | ||
| 5 | DHR | 6.4 | 6.5 | 156Md USD | 39.3x | 15.9 % | 5.5 % | 5.4 % | 2.0x | 3.5 % | 21.7 % | ||
| 6 | LONN | 6.3 | 6.1 | 46.9Md USD | Not meaningful (loss) | 16.7 % | 19.2 % | 8.7 % | 1.9x | 0.6 % | 9.2 % | ||
| 7 | A | 6.2 | 6.4 | 46.6Md USD | 32.5x | 19.5 % | 8.1 % | 13.9 % | 0.9x | 2.7 % | 39.7 % | ||
| 8 | TMO | 5.9 | 5.7 | 246Md USD | 35.8x | 15.0 % | 10.5 % | 7.9 % | 2.8x | 3.0 % | 44.5 % | ||
| 9 | WAT | 4.5 | 3.3 | 41.3Md USD | 105.0x | 3.6 % | 113.3 % | 1.4 % | 0.8x | 0.9 % | 49.4 % |
